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PURPOSE: To evaluate the use of subconjunctival bevacizumab on corneal neovascularization in an experimental
rabbit model for its effect on vessel extension, inflammation, and corneal epithelialization.
METHODS: In this prospective, randomized, blinded, experimental study, 20 rabbits were submitted to a chemical
trauma with sodium hydroxide and subsequently divided into two groups. The experimental group received a
subconjunctival injection of bevacizumab (0.15 m; 3.75 mg), and the control group received an injection of 0.15 ml
saline solution. After 14 days, two blinded digital photograph analyses were conducted to evaluate the
inflammation/diameter of the vessels according to pre-established criteria. A histopathological analysis of the
cornea evaluated the state of the epithelium and the number of polymorphonuclear cells.
RESULTS: A concordance analysis using Kappa’s statistic showed a satisfactory level of agreement between the two
blinded digital photography analyses. The neovascular vessel length was greater in the control group (p,0.01)
than in the study group. However, the histopathological examination revealed no statistically significant
differences between the groups in terms of the state of the epithelium and the number of polymorphonuclear
cells.
CONCLUSIONS: Subconjunctival bevacizumab inhibited neovascularization in the rabbit cornea. However, this drug
was not effective at reducing inflammation. The drug did not induce persistent corneal epithelial defects.
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INTRODUCTION
Ocular trauma, infection, inflammation, and degeneration
result in corneal neovascularization.1 Neovessels cause
structural changes that allow the overflow of fluid to the
extravasculature, blood stasis and hemorrhage, and they
can reduce corneal transparency with subsequent and
progressive vision impairment.1 Corneal neovascularization
is one of the greatest risk factors for corneal transplant
rejection2 because it allows leukocytes access to donor tissue
antigens.
Corticosteroids are the first-line treatment for corneal
neovascular diseases because of their ability to reduce the
inflammatory process4 and vascular proliferation, both of
which are initiated soon after the ocular trauma.5 However,
side effects related to the non-specificity of corticosteroids
limits their use. Such side-effects include the increased risk
of cataracts and glaucoma due to high intra-ocular pressure
(IOP).6
Vascular endothelial growth factor (VEGF) and its recep-
tors play an important role in the neovessel formation that is
observed in diabetic retinopathy, venous retinal occlusion,
age-related macular degeneration, and corneal neovascular-
ization.7 High VEGF expression was observed in neovascu-
larized corneas after penetrating keratoplasty in corneal
inflammatory diseases8 and in guinea pigs’ corneas that were
burned by alkalis during the healing process.9 Anti-VEGF
drugs have sparked a revolution in the treatment of
neovascular diseases by reducing neovascularization and
also by their supposed action on fibroblasts.10 These drugs
can provide beneficial effects after intra-vitreous injection in
age-related macular degeneration (ARMD) neovasculariza-
tion, diabetic retinopathy, and glaucoma, with minimal
toxicity or side effects.11 These effects may also include the
reduced formation of new vessels in other regions of the eye.
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The aim of this prospective study was to investigate the
effects of subconjunctival injections of bevacizumab on
experimentally induced corneal neovascularization by
focusing on the neovessel length, inflammation, and re-
epithelization.
MATERIALS AND METHODS
This prospective, randomized, blinded study was per-
formed at the Instituto de Pesquisas Me´dicas (IPEM) of the
Faculdade Evange´lica do Parana´ (FEPAR) - Brazil and
Hospital Universita´rio Evange´lico de Curitiba (HUEC). The
Animal Experimentation Norms and Principles proposed by
the Cole´gio Brasileiro de Experimentac¸a˜o Animal (1994)
were followed.
The studied variables include the vessels’ lenght, degree
of inflammation/diameter, epithelium integrity, and num-
ber of polymorphonuclear cells (PMN).
Intervention
Twenty corneas of twenty New Zealand rabbits were
studied. All rabbits were healthy male albinos, weighing
between 2.300 and 2.500 kg and were three to four months
old.
The rabbits were intramuscularly anesthetized with xyla-
zine hydrochloride 0.1 ml/Kg (2.3 mg/kg) and ketamine
hydrochloride 0.2 ml/Kg (10 mg/kg). The animals were
divided randomly into a control group (Group 1) (n= 10)
and a study group (Group 2)(n= 10).
The left corneas of the animals were exposed to 1 N
sodium hydroxide (NaOH), through a 5 mm diameter filter
paper that was applied to the superior cornea tangential of
the limbus for 20 seconds, followed by washing with 20 ml
of 0.9% saline solution. Subsequently, the control group
animals received a subconjunctival injection of 0.15 ml of
0.9% saline solution, whereas the study group animals
received a subconjunctival injection with 0.15 ml (3.75 mg)
of bevacizumab (Figure 1). The injections were performed
superiorly and close to the burned area. One surgeon
performed all of the procedures in a blinded fashion.
The rabbits in Groups 1 and 2 were again anesthetized,
examined and digitally photographed 14 days after the
corneal burn and were euthanized by a 5-ml intramuscular
sodium pentobarbital injection. Subsequently the corneas
were removed, maintaining a scleral margin of 3 mm, fixed
in formalin for 24 hours and submitted for histopathological
study with hematoxylin-eosin. The corneal epithelium
integrity, or lack thereof, and the number of PMN cells
per field were observed at a magnification of 400x using an
optical microscope. The most damaged field in the opacity
area was utilized.
Digital images were obtained to examine the vessel
extent and the vessel inflammation/diameter in the frontal
position using a Sony CybershotH (Sony Corporation –
Tokyo/Japan) 7.2-megapixel camera, which was supported
by a fixed tripod with an accessory ZeissH (Carl Zeiss AG –
Oberkochen/Germany) lens with a magnification of 40x at
a distance of 5 cm. Each animal was submitted to two
digital photography evaluations for each variable (vessel
extent and vessel inflammation/diameter). A cornea
specialist performed the two evaluations of the digital
pictures in a blinded and randomized fashion. The corneal
neovascularization was determined using a score given by
the cornea specialist according to the vessel extent and
inflammation/diameter degree observed.
The vessel extent was determined using a scale from 0 to 4
(0 – no vessels on the corneal limbus; 1 – vessels that
advanced over the corneal limbus, covering 0-25% of the
burned area; 2 – vessels that reached 25-50% of the burned
area; 3 – vessels that reached 50-75% of the burned area;
4 – vessels that extended to the entire burned area).
The inflammation and diameter degree on the vessels
were determined using a scale from 0 to 3: (0 – no
inflammation or vessels; 1 – little inflammation and vessels
of small diameter; 2 – moderate inflammation and vessels of
medium diameter; 3 – intense inflammation and vessels of
large diameter).
Statistical Analysis
To validate the evaluation model, the reproducibility
of these measurements was evaluated using the Kappa
statistic.
For each evaluation, the two groups were compared with
respect to the ordinal variables by using the Mann-Whitney
non-parametrical test. The group comparison for dichot-
omous variables was executed using the Fisher exact test.
p,0.05 indicated statistical significance.
RESULTS
On the seventh day after the corneal burn, a rabbit from
the study group presented corneal perforation and was
excluded from the research. Thus, 19 animals were left in
the study, including ten from the control group and nine
from the study group.
The digital pictures of each animal were submitted to two
evaluations for each variable, as shown in Table 1 (control
group) and Table 2 (study group).
Figure 1 - Animal 8 from the control group showing the vessel
extent reaching 75% of the burned area and intense inflamma-
tory reaction (Degree 3).
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Animal 8 of the control group (Figure 1) had a cornea
classified as degree 3 in both evaluations (vessels reaching
up to 75% of the burned area) according to the vessel extent
criteria and inflammatory reaction (intense inflammation
and vessels of large diameter). Animal 5 of the study group
(Figure 2) had a cornea classified as degree 1 for both vessel
extent criteria (vessels advancing over the corneal limbus,
reaching up to 25% of the burned area) and inflammatory
reaction (little inflammation and small-diameter vessels).
The concordance analysis of the vessel extent estimated
by the Kappa coefficient was 0.705 (95% confidence interval:
0.514 – 0.895), which indicates a high level of agreement
between the two evaluations. The estimated Kappa coeffi-
cients for each of the vessel extent classifications are
presented in Table 3. The concordance was better character-
ized at the most extreme degrees (1 and 4).
Regarding the vessel inflammation/diameter, the esti-
mated Kappa coefficient between the two blinded evalua-
tions was 0.500 (95% confidence interval: 0.269 – 0.731),
which again indicates a satisfactory level of agreement
between the two evaluations. The estimated Kappa coeffi-
cients for each classification of vessel diameter are presented
in Table 4.
Although a satisfactory level of reproducibility was found
in the evaluations of large diameter vessels, the concordance
seemed to be weak at Degrees 1 and 2, indicating a difficulty
in distinguishing between little and moderate inflammation.
The comparison among the study and control groups
considered the average of the two evaluations. The null
hypothesis of the same results in both groups was tested
versus the alternative hypothesis of different values for the
considered variable.
The analysis of the vessel extent showed a significant
difference between the control and the study group, with
smaller vessels being found 14 days after the chemical burn
in the study group (Table 5). Nevertheless, no meaningful
difference was found among the same groups during the
same follow-up when evaluating the vessel inflammation
and diameter (Table 6).
The microscopic evaluation of the corneal epithelial
integrity revealed that the epithelium of all corneas from
the study group had healed at 14 days compared with 60%
in the control group (Table 7). Despite the reduced number
of corneas that had epithelized in the control rabbits, no
statistically significant difference was found between the
groups.
A lower number of polymorphonuclear cells was found in
the treated group compared with the control group. Figure 3
shows the polymorphonuclear infiltration in Animal 1 of the
control group, whereas Figure 4 shows Animal 3 of study
group, which displayed little polymorphonuclear infiltra-
tion and full corneal epithelium integrity. In spite of the
discrepancies among some rabbits (Figures 3 and 4) and an
overall lower number of PMNs being found in the study
group, no meaningful statistical differences among the
groups were encountered in terms of PMN cell number
(Figure 5).
DISCUSSION
Previous studies used subconjunctivally administered
bevacizumab at dosages varying from 1.25 mg to
3.75 mg.6,12,13 In this study, we chose a dose of 3.75 mg.
Because we were only administering one injection during
the study, we wanted a high dose that would suppress the
initial angiogenic stimulus. No drug-related toxicity has
been reported using this concentration. Hurmeric et al.13
compared the effect of injected bevacizumab when it was
Table 1 - Blinded photographic analysis of vessel extent
and inflammation/diameter in the control group,
fourteen days after chemical burn.
Animal Vessel Extent Vessel Inflammation/Diameter
Evaluation 1 Evaluation 2 Evaluation 1 Evaluation 2
1 2 3 1 1
2 3 3 2 2
3 2 2 2 1
4 2 3 1 1
5 3 3 2 2
6 3 3 2 2
7 4 4 1 1
8 3 3 3 3
9 3 3 3 3
10 2 2 1 2
Table 2 - Blinded photographic analysis of vessel extent
and inflammation/diameter in the study group, fourteen
days after the corneal burn.
Animal Vessel Extent Vessel Inflammation/Diameter
Evaluation 1 Evaluation 2 Evaluation 1 Evaluation 2
1 1 1 2 2
2 1 1 3 3
3 2 1 2 2
4 1 2 1 2
5 1 1 1 1
6 1 1 1 2
7 1 1 1 2
8 1 1 1 2
9 1 1 2 2
Figure 2 - Animal 5 from the study group showing the vessel
extent reaching up to 75% of the burned area and minimal
inflammatory reaction (Degree 1).
CLINICS 2011;66(8):1443-1449 Subconjunctival bevacizumab and corneal neovascularization
Mello GR et al.
1445
used immediately after the injury or at three days after the
injury. Better anti-angiogenic responses were found in the
group treated soon after the induced damage. Thus, we also
administered the subconjunctival injection soon after the
injury.
Vascular growth, which is mainly analyzed using the
angiogenesis parameters of vessel extent and degree of
inflammation, is usually determined through photographic
analysis.12,6 However, no established model for this analysis
was found. Thus, an experimental model of digital photo-
graphic analysis was established, which allowed the vessel
extent and inflammation/diameter to be evaluated within
the indicated time period. Other photographic evaluation
methods have been applied with pixel counting or
measurements. Although these methods give the impres-
sion of a mathematical certainty as they appear quantitative,
the data are subjective with regard to where the vessels
begin and end. In addition, the delineation of the affected
area may not be accurate when it is determined mathema-
tically. Thus, we have proposed a photographic clinical
analysis, in which the evaluator, who is a cornea specialist,
observes not only the vessel extent but also the vessel aspect
and inflammation degree.
We chose to evaluate the corneas at 14 days because
angiogenesis has shown a rapid growth until the 12th day in
other models.14 In the previous studies, the vessel extent
stabilized after this initial period. Fourteen days was
sufficient to produce the highest level for each variable
(vessel extent and inflammation).
On the seventh day, a rabbit from the study group
showed corneal perforation and was excluded from the
study. As only one rabbit showed perforation and the
remaining rabbits in the group showed an intact epithelium
by the end of the 14-day period, the perforation was
unlikely to be directly caused by the drug. The rabbit may
have had a bacterial infection in the wound that was
acquired early in the experiment when the corneal
epithelium was not fully healed.
Statistical analysis confirmed that the evaluation method
was excellent for identifying vessel extension at Degrees 1
and 4 and good for identifying vessel extension at Degrees 2
and 3. The method was also good for identifying vessel
inflammation/diameter, as indicated by the good agree-
ment between the two blinded evaluations. For this variable,
Degree 3 (intense inflammation and vessels of large
diameter) showed excellent agreement.
The results obtained show that this method may be
reproduced for the evaluation of other anti-angiogenic
drugs intended to reduce corneal neovascularization.
There was a statistically significant difference in the vessel
extent between the two groups, with a lesser extent in
the study group compared with the control group. These
data indicate a positive effect on the chemical burn
and agree with the data found in recent literature.12,13
Neovascularization is considered to be related to a poor
prognosis in corneal transplants because it interferes with
corneal transparency, which can result in low visual acuity.1
Thus, bevacizumab may improve the prognosis in cases
with progressive neovessels after penetrant keratoplasty or
in the case of some chemical burns, especially those that
require a corneal transplant.
The degree of inflammation was evaluated because
although the drug does not possess direct anti-inflamma-
tory actions, it does affect fibroblasts.15,16 Although its
action in acute inflammation is not fully understood, some
authors suggest that the drug decreases neutrophil invasion
within the wound.17 The results for inflammation/diameter
and the number of PMN cells showed that the drug does not
have a clinically meaningful anti-inflammatory effect, which
agrees with the theory that the inflammatory process has
many pathways and the inhibition of VEGF alone does not
significantly affect inflammation.
Through these data, we suggest that this treatment may
be more effective when administered along with corticos-
teroids, which would reduce the inflammation. Further
studies are necessary to determine whether concomitant
inhibition of inflammation and neovascularization leads to
massive cellular death by acute hypoxia, which may occur
because of the inhibition of all physiological mechanisms
involved in such ischemia.
Table 3 - Concordance analysis among evaluations with respect to vessel extent.
Classification Kappa CI 95% Concordance
Degree 0: no vessels on the corneal lamina - - -
Degree 1: vessels that advanced over the corneal limbus, reaching up
to J of the burned area
0.863 0.541 – 1 Excellent
Degree 2: vessels that advanced over the corneal limbus, reaching up
to K of the burned area
0.471 0.149 – 0.794 Good
Degree 3: vessels that advanced over the corneal limbus, reaching up
to 3/4 of the burned area
0.644 0.322 – 0.967 Good
Degree 4: vessels that extended throughout the entire burned area 0.824 0.502 – 1 Excellent
CI – confidence interval.
Table 4 - Concordance analysis among the evaluations with respected to vessel diameter/inflammation.
Classification Kappa CI 95% Concordance
Degree 0: no vessels or inflammation - - -
Degree 1: little inflammation, vessels of small diameter 0.383 0.061 – 0.706 Weak
Degree 2: moderate inflammatory reaction, medium diameter vessels 0.339 0.017 – 0.661 Weak
Degree 3: intense inflammatory reaction, vessels of large diameter 0.853 0.531 – 1 Excellent
CI – confidence interval.
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The integrity of the corneal epithelium was evaluated
on the 14th day because the drug may have affected
the healing process and delayed wound healing. Rapid
restoration of the epithelium is fundamental to the healing
process and prevents wound contamination. The compar-
ison between the two groups did not show persistent
epithelial defects in the study group at the end of the
follow-up. The results showed fewer corneas with an
exposed stroma in the study group compared with the
control group. However, no statistical difference was
observed between the groups, which suggests that the
drug did not impair epithelial healing. This study
suggests that the bevacizumab has potential for use
during the acute healing stage, in which the epithelium
is still open. Corticosteroids should be used carefully
during this stage because they may impair epithelial
healing.18
Delayed epithelial healing has been described pre-
viously19,20 and is believed to be caused by the reduced
expression of surface integrins and collagens, which
interferes with epithelial cell adhesion. However, these
studies were performed with higher doses that were applied
topically several times a day. Kim et al. showed a dose-
related effect.20 Thus, we suggest that the subconjunctival
administration is safer because in our study, it did not
jeopardize the re-epithelialization.
Chalam et al.21 showed that bevacizumab is not toxic
to corneal cells or fibroblasts when administered in
concentrations up to 25 mg/ml. This finding is supported
by the current study, in which there was no inhibition of
re-epithelialization.
Although the neovascularization induced by the burn
was suppressed, the suppression was not as complete as
has been described in previous studies.12 This is possibly
because VEGF is not the only factor responsible for
angiogenesis. Other pro-angiogenic factors, such as TGF-
beta and fibroblast growth factor, may still be involved.16
We suggest that bevacizumab should not to be used as a
monotherapy; instead, it should serve as one aspect of a
multi-factorial treatment alongside other drugs, such as
corticosteroids, in acute cases. This association has not
been fully studied, and some conflicting results have been
reported. Using a rabbit model, Kang et al.22 showed that
a combined treatment of bevacizumab and triamcinolone
acetonide was no more effective than the use of bevaci-
zumab alone. Another study23 examined the inhibition of
neovascularization in a rat model using bevacizumab
alone and with dexamethasone. However, again there was
no clear advantage when dexamethasone was included.
Table 5 - Analysis of vessel extent among the groups.
Group n Median Minimum Maximum p-value
Control 10 3 2 4
Study 9 1 1 1.5 ,0.001*
*Mann-Whitney non-parametric test.
Table 6 - Vessel inflammation/diameter analysis among
the groups.
Group n Median Minimum Maximum p-value
Control 10 1.75 1 3
Study 9 1.5 1 3 =0.968*
*Mann-Whitney non-parametric test.
Table 7 - Comparative analysis among the groups
regarding the epithelial integrity 14 days after the
chemical burn.
EPITHELIUM
DEFECT GROUP
Control Study
YES 4 0
40.0% 0.0%
NO 6 9
60.0% 100.0%
Total 10 9
p-value: 0.087
Fischer’s exact test.
Figure 3 - Histopatology of the cornea from Animal 1 of the
control group with intense polymorphonuclear infiltration.
Figure 4 - Cornea from Animal 3 of the study group with little
polymorphonuclear infiltration and full corneal epithelium
integrity.
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Newer anti-angiogenic drugs have also been studied over
the last year with promising results. For example, suramin
is a non-specific anti-angiogenic drug that has a longer
half-life than bevacizumb. It has been suggested that this
association could provide a more potent and longer
effect.24 Pe´rez-Santonja et al.25 showed a greater inhibition
of the neovessels by sunitinib (an anti-VEGF and anti-
PDGF drug) compared with bevacizumab.
It has been found that established neovessels, such as
those in diabetic retinopathy, are re-established after the
drug is discontinued, thereby requiring additional treat-
ments.26 The drug’s effect has not been extensively studied
in cases of acute neovascularization, such as that following
burns or the initial neovessel growth following a corneal
transplant. It is also possible that if the angiogenic stimulus
is reduced by specific inhibitors such as bevacizumab in
the acute stage, neovessel formation may decrease in the
long-term because the angiogenic stimulus has a short
duration and is not maintained by the injury’s physio-
pathology as it is in diseases such as diabetic retinopathy.
Thus, this treatment could have a positive effect in the
long-term for some treatments such as subsequent corneal
transplants.
Anti-angiogenic drugs have a great potential for
beneficial effects in severely neovascularized eyes with
little or no limbal damage, which generally present with
very low visual acuity. Presently, there is no available
treatment for this condition. Further studies with different
dosages and steroids combinations with the various VEGF
inhibitors that compare not only the neovascularization
itself but also the inflammatory response and side effects
would contribute to the search for an ideal treatment. This
association may have a synergistic effect on burns or in
cases with a possibility of acute neovascularization, where
the neovascular stimulus occurs as a part of the acute
inflammatory response.
Thus, we conclude that the subconjunctival adminis-
tration of bevacizumab efficiently reduces corneal neo-
vascularization without inducing persistent epithelial
defects following a chemical burn. However, this treat-
ment does not show meaningful anti-inflammatory
effects.
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